VCEL Vericel Corporation

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY on Wednesday, February 14, 2018 at 9:00am Eastern Time.

The presentation will be live webcast at: http://wsw.com/webcast/leerink30/vcel/, and may be accessed from the news and events section of the Vericel website.

About Vericel CorporationVericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.

Global Media Contacts:David SchullRusso Partners LLC+1 212-845-4271 (office)+1 858-717-2310 (mobile)David.schull@russopartnersllc.com

Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1 917-547-0434 (mobile)Karen.chase@russopartnersllc.com

Investor Contacts:Chad RubinThe Trout Groupcrubin@troutgroup.com+1 (646) 378-2947

Lee SternThe Trout Grouplstern@troutgroup.com+1 (646) 378-2922